Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region

The development of new diagnostic tools and targeted therapy have significantly improved the management of non-Hodgkin's malignant lymphomas and thus their long-term prognosis. However, in the study of improved patient management, survival is not the only measurable indicator and preservation of quality of life is an essential component. In addition, there is little existing data regarding the determinants of quality of life in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) in the general population in France.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diffuse Large Cell Diffuse Lymphoma Follicular Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Dijon Bourogne

Dijon, 21000, France

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with DLBCL or FL between January 1, 2010 and December 31, 2017,
Alive as of January 1, 2021,
Updated patient address.

Exclusion criteria

Other forms of Hematologic Malignancies at diagnosis,
Minors.
Person subject to legal protection (curatorship, guardianship)
Person subject to a judicial safeguard measure
Pregnant, parturient or breastfeeding woman
Adults incapable of giving consent

Treatment and study plan

questionnaires

Other

QLQ-C30, SF-12, HADS, SARASON, EPICES, socio-professional data

Collection of clinical data and treatments

Other

clinical data and treatments

Primary outcomes

Generic Questionnaire SF-12

Time frame: At inclusion
Specific questionnaire QLQ-C30

Time frame: At inclusion

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Acronym: LymphoVi

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2021
First posted: Apr 26, 2021
Registry last updated: Feb 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed